Werewolf Therapeutics, Inc. - HOWL STOCK NEWS

Werewolf Therapeutics (Nasdaq: HOWL) will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The pre-recorded presentation will be available on-demand starting 7:00 AM EDT on September 12. Werewolf is focused on conditionally activated therapeutics that stimulate the immune system targeting cancer. Their leading candidates, WTX-124 and WTX-330, aim to improve treatment for solid tumors by activating selectively within the tumor microenvironment while remaining inactive elsewhere.

Werewolf Therapeutics announced the first patient has been dosed in the Phase 1/1b trial for WTX-124, its leading INDUKINE™ molecule targeting IL-2 for treating solid tumors. This multi-center, open-label trial will evaluate WTX-124 alone and with KEYTRUDA® in patients with advanced solid tumors who have not responded to standard care. The innovative design aims to minimize toxicities associated with conventional IL-2 therapy while enhancing anti-tumor activity in the tumor microenvironment. This pivotal milestone reflects Werewolf's commitment to advancing its oncology pipeline.

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) reported significant advancements in its clinical development, including FDA clearance for WTX-124, its lead candidate for treating advanced solid tumors. The IND application for WTX-330 is set for submission in 2H22. The company holds a strong cash position of $145.7 million, expected to sustain operations through Q4 2023. Collaboration revenue reached $4.1 million due to an upfront payment from Jazz Pharmaceuticals, though R&D expenses increased to $13.9 million, leading to a net loss of $14.6 million for Q2 2022.

Werewolf Therapeutics (Nasdaq: HOWL) will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9-10, 2022. The company focuses on developing conditionally activated therapeutics to enhance the immune system for cancer treatment. Utilizing its proprietary PREDATOR™ platform, Werewolf aims to create molecules that activate selectively within the tumor microenvironment, minimizing side effects. Key product candidates include WTX-124 and WTX-330, both targeting solid tumors and designed to work with immune checkpoint inhibitors. For more information, visit www.werewolftx.com.

Werewolf Therapeutics (Nasdaq: HOWL), an innovative biopharmaceutical company focused on cancer treatments, announced that Dr. Randi Isaacs, Chief Medical Officer, will participate in a fireside chat at 9:00 AM ET on June 9, 2022, during the Jefferies Global Healthcare Conference in New York. The event is scheduled from June 8-10, 2022. A live webcast will be available, and an archived replay will be accessible for 30 days. Werewolf is pioneering therapeutics that stimulate the immune system using its proprietary PREDATOR™ platform, aiming to enhance treatment for solid tumors.

Werewolf Therapeutics (HOWL) has entered an exclusive global licensing and collaboration agreement with Jazz Pharmaceuticals for WTX-613, an investigational cytokine pro-drug for cancer treatment. The deal includes a $15 million upfront payment and potential milestones totaling $1.26 billion, along with royalties on future sales. Additionally, preclinical data for two lead molecules, WTX-124 and WTX-330, has been presented, supporting their development timelines. As of Q1 2022, Werewolf reported a cash balance of $143.7 million, sufficient to fund operations through at least Q4 2023.

Werewolf Therapeutics (HOWL) presented promising preclinical data on its IL-2 and IL-12 INDUKINE molecules, WTX-124 and WTX-330, at the AACR Annual Meeting. WTX-124 demonstrated high tumor selectivity and significant anti-tumor activity via CD8+ T cells, showing a better therapeutic window than recombinant IL-2. WTX-330 exhibited potent anti-tumor immunity and a notable therapeutic window compared to IL-12. The company plans to file IND applications for both candidates in 2022, with WTX-124 evaluated in collaboration with Merck's KEYTRUDA.

Jazz Pharmaceuticals has entered a licensing agreement with Werewolf Therapeutics for WTX-613, an innovative immuno-oncology therapy. Jazz will pay $15 million upfront, with up to $1.26 billion in potential milestone payments. WTX-613 aims to enhance cancer treatment by minimizing systemic toxicity associated with conventional therapies. This program expands Jazz's oncology pipeline, with an IND application planned for submission in 2023. Both companies express optimism about the collaboration and the future potential of WTX-613 in treating various cancers.

Werewolf Therapeutics (Nasdaq: HOWL) reported a net loss of $50 million for 2021, up from $15 million in 2020. The company's cash position improved, with $157.5 million as of December 31, 2021, resulting from a successful IPO that raised $120 million. In 2022, Werewolf plans to file IND applications for its lead candidates, WTX-124 and WTX-330. Positive preclinical data has been reported for these molecules, demonstrating anti-tumor responses. The company has strengthened its management team and has been added to the Nasdaq Biotechnology Index.